Robert Orenstein, DO

Infectious Disease Specialist
Mayo Clinic in Arizona
Phoenix, AZ

Disclosure: Rebiotix Inc.: Advisor or Review Panel member

Presentation(s):

• LB5 - A Long Time Coming: Final Two-Year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections

  Thursday, October 3
  2:25 PM – 2:35 PM